Mineralys Therapeutics, Inc. MLYS
25.86
(0.73)
(2.75%)
as of 25 Sep
- Market cap
- $2.4B
- P/E
- 0.0×
Follow MLYS
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
34.46 | 44.33 | 43.76 | 25.50 |
+8 more quarters Free account |
Net Debt/EBITDA |
2.29 | 14.25 | 17.16 | 14.44 | |
Debt/Assets |
14.62% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.18 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.14 | 1.00 | 1.18 | 0.78 | |
Capex/Depreciation |
0.00 | 0.00 | (1.15) | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.38) | (0.48) | (0.56) | (0.41) | |
Cash per Share |
7.81 | 7.80 | 9.71 | 8.41 | |
Shareholders Equity per Share |
6.50 | 7.70 | 9.56 | 8.17 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
6.50 | 7.70 | 9.56 | 8.17 | |
Free Cash Flow |
(32.56) | (39.47) | (37.90) | (28.87) | |
Working Capital |
646.48 | 637.75 | 646.27 | 576.28 | |
Capital Expenditures |
— | — | (0.01) | — | |
Net Current Asset Value |
548.87 | 637.75 | 646.27 | 576.28 | |
| Other line items | |||||
Quick Ratio |
34.24 | 43.90 | 43.45 | 25.24 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.38) | (0.48) | (0.56) | (0.41) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
2.12 | 0.74 | 1.25 | 2.11 | |
Average Assets |
501.79 | 503.90 | 433.85 | 434.10 | |
Average Common Equity |
432.23 | 489.85 | 418.98 | 406.68 | |
Capex to Sales |
— | — | 0.00 | — | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates